NeuroSense Therapeutics Faces Nasdaq Compliance Hearing
Ticker: NRSNW · Form: 6-K · Filed: Aug 26, 2024 · CIK: 1875091
Sentiment: neutral
Topics: compliance, listing-rules, sec-filing
TL;DR
NeuroSense Therapeutics is fighting to stay on Nasdaq after falling below the $2.5M equity minimum; hearing held Aug 1.
AI Summary
NeuroSense Therapeutics Ltd. received a notice on June 21, 2024, that it had not regained compliance with Nasdaq's Listing Rule 5550(b) because its stockholders' equity fell below the required $2,500,000 minimum. The company requested a hearing before the Nasdaq Panel, which took place on August 1, 2024.
Why It Matters
Failure to regain Nasdaq compliance could lead to delisting, impacting the company's ability to raise capital and its stock liquidity.
Risk Assessment
Risk Level: medium — The company is at risk of delisting from Nasdaq if it cannot demonstrate compliance with listing rules.
Key Numbers
- $2,500,000 — Minimum Stockholders' Equity (The threshold NeuroSense Therapeutics failed to meet for Nasdaq compliance.)
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the 6-K report
- Nasdaq (company) — Stock exchange where the company is listed
- $2,500,000 (dollar_amount) — Minimum stockholders' equity required by Nasdaq
- June 21, 2024 (date) — Date the company received the non-compliance notice
- August 1, 2024 (date) — Date of the Nasdaq Panel hearing
FAQ
What specific rule did NeuroSense Therapeutics fail to comply with?
NeuroSense Therapeutics failed to comply with Nasdaq's Listing Rule 5550(b).
What was the reason for the non-compliance?
The company's stockholders' equity fell below the required minimum of $2,500,000.
When did NeuroSense Therapeutics receive the notice of non-compliance?
The company received the notice on June 21, 2024.
When was the hearing with the Nasdaq Panel held?
The hearing was held on August 1, 2024.
What is the company's principal executive office location?
The company's principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya, Israel.
Filing Stats: 337 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2024-08-26 08:00:08
Key Financial Figures
- $2,500,000 — y falling below the required minimum of $2,500,000. The Company promptly requested a heari
Filing Documents
- ea0212366-6k_neurosense.htm (6-K) — 11KB
- 0001213900-24-072385.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: August 26, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2